Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 16Completed 13Withdrawn 3Recruiting 3Active not recruiting 2Approved for marketing 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic 1

Interventions

Rituximab 15Cyclophosphamide 12fludarabine phosphate 11ibrutinib 10Bendamustine Hydrochloride 9fludarabine 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6venetoclax 4Whole-Body Irradiation 4Radiotherapy 4idelalisib 3duvelisib 3acalabrutinib 3Mycophenolic Acid 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Flow Cytometry 3Filgrastim 3Cytarabine 3Cyclosporine 3ofatumumab 2obinutuzumab 2Thiotepa 2Tacrolimus 2Pentetic Acid 2Etoposide 2Dexamethasone 2Dasatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Lymphocytic, Chronic, B-Cell × idelalisib × Clear all
NCT06205290 2024-04-02

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02662296 2017-09-27

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT01659047 2012-09-07

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Gilead Sciences

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡